Researchers are now investigating the potential of DC vaccines in treating breast cancer [242], particularly in patients with specific tumor antigens, such as HER2 [243], mucin 1 (MUC1) [244], or other tumor-associated markers that could be targeted through dendritic cell-based strategies. Here, ERBB2 is linked to breast carcinoma.